The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test

Myopia Clinical Trial

Official title:

The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00638430
• Other study ID #: Humphrey30-2
• Status: Completed
• Phase: N/A
• First received: March 12, 2008
• Last updated: March 12, 2008
• Start date: March 2007
• Est. completion date: March 2008

Study information

• Verified date: March 2008
• Source: Samsung Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: South Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to examine the effect of the myopic optical defocus on the Humphrey Matrix 30-2 test.

Description:

The Humphery Matrix (Zeiss, Dublin, California, USA; in cooperation with Welch Allyn, Skaneateles, New York, USA), which is a recently developed version of FDT perimetry, showed more improved technology to detect early glaucomatous damage. The user's guide for the Humphrey Matrix (Humphrey® matrix visual field instrument user's guide. Zeiss, Dublin, California, USA; in cooperation with Welch Allyn, Skaneateles, New York, USA; 2003) suggests that myopic refractive errors more than -3.0 D need to be corrected before the 30-2 test. However, the proper correction of the optical defocus is not always easy because of a lack of trial frame.

The purpose of the present study is twofold. At first, the influence of the low-grade myopia on the Humphery Matrix 30-2 test will be evaluated and compared to the effect of moderate-grade myopia. Secondly, the influence of myopic optical defocus and the glaucomatous visual field damage on the pattern deviation plot change according to the severity of glaucomatous visual field damage will be estimated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 2008
• Est. primary completion date: October 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 27 Years to 61 Years

Eligibility

Inclusion Criteria:

• intra-ocular pressure 23 or higher

• suspicious glaucomatous optic disc change

• suspicious defect of retinal nerve fiber layer

• or eyes with various degrees of glaucoma

Exclusion Criteria:

• a high myopic eye (SE more than -6.0 D)

• moderate to severe cataract

• evidence of diabetic or hypertensive retinopathy

• macular disease

• intra-ocular inflammation

• history of intraocular surgery and any other ocular lesion that could have an influence on the perimetry result

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Myopia

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (1)

Anderson AJ, Johnson CA. Frequency-doubling technology perimetry and optical defocus. Invest Ophthalmol Vis Sci. 2003 Sep;44(9):4147-52. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mean defect		15 minutes	No